Science Current Events | Science News | Brightsurf.com
 

Extra-aggressive form of idiopathic pulmonary fibrosis identified

May 30, 2007
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis. The disease is characterized by the insidious onset of dyspnea or cough and usually evolves slowly.

Now, Selman and coworkers present in an article published in the online, open-access journal PLoS ONE on Wednesday 30th May, strong evidence indicating that a subset of IPF patients has a short duration of symptoms before diagnosis and display an accelerated clinical course to end-stage disease. The authors postulate that these "rapid progressor" patients, predominantly smoking males, represent a distinct clinical phenotype compared with the usual "slow progressors" patients.

"These findings highlight the variability in the progression and outcome of IPF, and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF," said Dr Selman, who is the Director of Research at the National Institute of Respiratory Research in Mexico City and the lead author on this publication. "They also suggest that physicians should pay more attention to the time of onset of symptoms, and to look for other signs that allow the identification of these rapid progressor patients".

In this study the authors performed global gene expression analysis and other molecular studies in a subset of patients and identified a number of genes that were differentially expressed in both groups, suggesting that rapid progressors are biologically distinct from slow progressors.

"While preliminary, these results may allow investigators to identify biomarkers of disease progression," said Dr King, who is the Chief of Medicine at San Francisco General Hospital and an internationally renowned expert in research and management of pulmonary fibrosis.

The senior author on this paper, Dr Naftali Kaminski, who is the Director of the Simmons Center for Interstitial Lung Disease at the University of Pittsburgh, added that this research highlighted the need to collect as much information on patients with IPF as possible. "We are only now starting to really understand the disease and characterize it," he said, "therefore, it is critical for patients with the disease to be seen in centers that are actively involved in IPF research."

Better identification and understanding of these differences may provide insights into the pathogenesis of IPF and assist in the development of therapeutic interventions for this devastating lung disease.

Public Library of Science


Related Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News Articles


Increased protein turnover contributes to the development of pulmonary fibrosis
Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis.

Rapid skin improvement seen after treating systemic sclerosis patients with fresolimumab
A major treatment breakthrough for total body scarring of the skin that occurs in patients with systemic sclerosis (SSc), also known as scleroderma, may soon be available for the estimated 300,000 Americans who suffer with this condition.

Study provides insights on chronic lung disease
A new study shows that shorter telomeres--which are the protective caps at the end of a cell's chromosomes--are linked with worse survival in a progressive respiratory disease called idiopathic pulmonary fibrosis (IPF).

UGA researchers find potential treatment for fatal lung diseases
Researchers at the University of Georgia have discovered that the drug triciribine may reverse or halt the progression of pulmonary fibrosis and pulmonary hypertension, two respiratory diseases that are almost invariably fatal.

New approach for treating idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

Mutations in 2 genes linked to familial pulmonary fibrosis and telomere shortening
Researchers at UT Southwestern Medical Center have identified mutations in two genes that cause a fatal lung scarring disease known as familial pulmonary fibrosis.

New method enables drug target validation for COPD treatment
Together with clinical partners, a team led by Dr. Dr. Melanie Königshoff and the doctoral student Franziska Uhl at the Comprehensive Pneumology Center of Helmholtz Zentrum München have investigated, for the first time, the suitability of Wnt/beta-catenin.

Childhood syndrome combining lung disease, arthritis is identified
Using the latest genome sequencing techniques, a research team led by scientists from UC San Francisco (UCSF), Baylor College of Medicine, and Texas Children's Hospital has identified a new autoimmune syndrome characterized by a combination of severe lung disease and arthritis that currently has no therapy.

Gene in high-altitude cattle disease sheds light on human lung disease
Vanderbilt University researchers have found a genetic mutation that causes pulmonary hypertension in cattle grazed at high altitude, and which leads to a life-threatening condition called brisket disease.

One type of airway cell can regenerate another lung cell type
A new collaborative study describes a way that lung tissue can regenerate after injury.
More Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News Articles

Pulmonary Fibrosis: Coping With a Terminal Disease

Pulmonary Fibrosis: Coping With a Terminal Disease
by Lifestyle Design Solutions


Pulmonary Fibrosis: Coping With a Terminal Disease by Robert Post

What do you do when you learn you have Pulmonary Fibrosis, a terminal disease for which there is presently no cure? The author relates his personal experience and explains how he has learned to cope with the disease, products and methods he uses for maintaining health and combating progression of the disease and explains how you can, too.

A linked resources section gives advice on finding and using support groups and Pulmonary Rehabilitation programs. Products and sources are identified that the author has found to be beneficial or vital for health maintenance.

This publication contains frank material that some may find disturbing to read but the author feels the patient and their caregiver...

Breathing Should Never Be Hard Work: One Man's Journey with Idiopathic Pulmonary Fibrosis

Breathing Should Never Be Hard Work: One Man's Journey with Idiopathic Pulmonary Fibrosis
by Robert Davidson (Author)


Robert Davidson was diagnosed with Idiopathic Pulmonary Fibrosis in October 2007 after having difficulties with the fitness test necessary to retain senior level soccer referee status. Rather than give in to the disease and die, he decided to fight and live as normal a life as possible, borrowing from Winston Churchill, the mantra "Never surrender". He and his wife, Heather, believe it was this attitude that led to him "winning" a double lung transplant January 30, 2010, just weeks before he would have died from the disease. This book is about his journey with that life threatening disease. Although it "steals away the sufferer's breath" Robert travelled to China (finding 12,800 feet up the Himalayas too high) and to the highlands of Scotland for his wife's 60th birthday celebration. ...

Improving Fibrosis in 30 Days

Improving Fibrosis in 30 Days
by Naturally Healthy Publications


Improving Fibrosis in 30 Days includes a rehabilitation plan to improve your pulmonary fibrosis symptoms and to attain long term health.

Journey of the CareGiver: Battling Pulmonary Fibrosis

Journey of the CareGiver: Battling Pulmonary Fibrosis
by MS, Lois Moody RN (Author)


The latest edition of this book (Surviving Caregiving) is available for the same price at: www.amazon.com/Surviving-Caregiving-Challenges-Lois-Moody/dp/1501029878/ref=sr_1_4?ie=UTF8&qid=1410298234&sr=8-4&keywords=surviving+caregiving

Idiopathic Pulmonary Fibrosis: Advances in Diagnostic Tools and Disease Management

Idiopathic Pulmonary Fibrosis: Advances in Diagnostic Tools and Disease Management
by Hiroyuki Nakamura (Editor), Kazutetsu Aoshiba (Editor)


From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to...

Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide (Respiratory Medicine)

Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide (Respiratory Medicine)
by Keith C. Meyer (Editor), Steven D. Nathan (Editor)


Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide delivers a concise review of our current understanding of disease pathogenesis and provides current evidence in the medical literature regarding its diagnosis and management. Each chapter includes key points and a summary aiming to update clinicians about various issues concerning the diagnosis and management of IPF. In addition to outlining the current state of knowledge, each chapter also provides a summary of ongoing research and identifies the needs for future research in the field. Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide is an important new text that provides its readers with a better understanding of the pathobiology and natural history of IPF as it continues to evolve.

Improving Lung Health in 30 Days: Pulmonary Rehabilitation Plan for COPD, Emphysema, Fibrosis, Bronchiectasis and More

Improving Lung Health in 30 Days: Pulmonary Rehabilitation Plan for COPD, Emphysema, Fibrosis, Bronchiectasis and More
by Robert Redfern (Author)


Improving Lung Health in 30 Days includes a rehabilitation plan to recover lung health and improve pulmonary conditions such as bronchitis, bronchiectasis, COPD, cystic fibrosis and emphysema amongst others.

Ruppel's Manual of Pulmonary Function Testing, 10e (Manual of Pulmonary Function Testing (Ruppel))

Ruppel's Manual of Pulmonary Function Testing, 10e (Manual of Pulmonary Function Testing (Ruppel))
by Carl Mottram BA RRT RPFT FAARC (Author)


Covering common pulmonary function tests and techniques, Ruppel's Manual of Pulmonary Function Testing, 10th Edition is not only an authoritative, on-the-job reference, but an excellent resource for preparing for the CPFT (certified pulmonary function technologist) and RPFT (registered pulmonary function technologist) specialty credentialing examinations. It includes information on pathophysiology, equipment, and quality assurance, so you can develop the testing skills you need to find and assess lung abnormalities and conditions including asthma, chronic bronchitis, emphysema, and cystic fibrosis. Written by Carl Mottram, RRT, RPFT, FAARC, one of the most respected experts in pulmonary function procedures, this text helps you get accurate test results every time.Case studies provide...

Cardiovascular and Pulmonary Physical Therapy: Evidence to Practice, 5e

Cardiovascular and Pulmonary Physical Therapy: Evidence to Practice, 5e
by Donna Frownfelter PT DPT MA CCS RRT FCCP (Author), Elizabeth Dean PhD PT (Author)


Providing a solid foundation in cardiovascular and pulmonary physiology and rehabilitation, Cardiovascular and Pulmonary Physical Therapy: Evidence and Practice, 5th Edition uses the latest scientific literature and research in covering anatomy and physiology, assessment, and interventions. A holistic approach addresses the full spectrum of cardiovascular and pulmonary physical therapy from acute to chronic conditions, starting with care of the stable patient and progressing to management of the more complex, unstable patient. Both primary and secondary cardiovascular and pulmonary disorders are covered. In this edition, updates include new, full-color clinical photographs and the most current coverage of techniques and trends in cardiopulmonary physical therapy. Edited by Donna...

First Aid for the USMLE Step 1 2015

First Aid for the USMLE Step 1 2015
by Tao Le (Author), Vikas Bhushan (Author)


THE 25th EDITION OF THE WORLD'S MOST POPULAR MEDICAL REVIEW BOOK! Trust 25 years of experience for the most effective USMLE Step 1 preparation possible 1,250+ must-know topics provide a complete framework for your USMLE preparation Test-taking advice with focus on high-efficiency studying Major revisions in all subject areas based on feedback from thousands of students Free real-time updates and corrections at www.firstaidteam.com Extensive faculty review process with nationally known USMLE instructors 1,000+ color photos and diagrams help you visualize high-yield concepts Expanded guide to high-yield study resources, including mobile apps INSIDER ADVICE FOR STUDENTS FROM STUDENTS

© 2015 BrightSurf.com